Silexion Therapeutics Corp. Files 8-K for Material Agreement
Ticker: SLXNW · Form: 8-K · Filed: Sep 26, 2025 · CIK: 2022416
Sentiment: neutral
Topics: material-agreement, corporate-action
Related Tickers: SLXN
TL;DR
Silexion Therapeutics signed a big deal, filing an 8-K on Sept 26, 2025.
AI Summary
Silexion Therapeutics Corp. (formerly Biomotion Sciences) entered into a material definitive agreement on September 26, 2025. The company, incorporated in the Cayman Islands, is a biological products company based in Ramat Gan, Israel. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing indicates a significant new development or contract for Silexion Therapeutics, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — An 8-K filing signals a material event, which could be positive or negative, introducing uncertainty until more details are disclosed.
Key Numbers
- 001-42253 — Commission File Number (SEC File Number for Silexion Therapeutics Corp.)
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- September 26, 2025 (date) — Date of earliest event reported
- Cayman Islands (jurisdiction) — State of incorporation
- Ramat-Gan, Israel (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Silexion Therapeutics Corp. on September 26, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into on September 26, 2025.
What was Silexion Therapeutics Corp. formerly known as?
Silexion Therapeutics Corp. was formerly known as Biomotion Sciences.
In which jurisdiction is Silexion Therapeutics Corp. incorporated?
Silexion Therapeutics Corp. is incorporated in the Cayman Islands.
Where are Silexion Therapeutics Corp.'s principal executive offices located?
Silexion Therapeutics Corp.'s principal executive offices are located at 12 Abba Hillel Road, Ramat-Gan, Israel.
What is the SIC code for Silexion Therapeutics Corp.?
The Standard Industrial Classification (SIC) code for Silexion Therapeutics Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 897 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-09-26 16:05:44
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
- $13.17 million — ng an aggregate offering price of up to $13.17 million (the "Shares"). Any sale of the Shares
Filing Documents
- zk2533809.htm (8-K) — 53KB
- exhibit_10-1.htm (EX-10.1) — 249KB
- 0001178913-25-003385.txt ( ) — 528KB
- slxn-20250926.xsd (EX-101.SCH) — 5KB
- slxn-20250926_def.xml (EX-101.DEF) — 18KB
- slxn-20250926_lab.xml (EX-101.LAB) — 27KB
- slxn-20250926_pre.xml (EX-101.PRE) — 20KB
- zk2533809_htm.xml (XML) — 6KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On September 26, 2025, Silexion Therapeutics Corp (the "Company"), entered into an At The Market Offering Agreement, (the "Offering Agreement"), with H.C. Wainwright & Co., LLC, as agent ("Wainwright"), pursuant to which the Company may offer and sell, from time to time through Wainwright ordinary shares of the Company, par value $0.0135 per share (the "Ordinary Shares"), having an aggregate offering price of up to $13.17 million (the "Shares"). Any sale of the Shares under the Offering Agreement will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus to be filed by the Company with the Securities and Exchange Commission (the "SEC"), on September 26, 2025, after such Registration Statement is declared effective by the SEC. Pursuant to the Offering Agreement, Wainwright may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended (the "Securities Act") including sales made by means of ordinary brokers' transactions, including on The Nasdaq Capital Market, at market prices or as otherwise permitted by law. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares pursuant to the Offering Agreement from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose. The Company is not obligated to make any sales of the Shares under the Offering Agreement. The offering of Shares pursuant to the Offering Agreement will terminate upon the earliest of (a) the sale of all of the Shares subject to the Offering Agreement and (b) the termination of the Offering Agreement by Wainwright or the Company, as permitted therein. The Company will pay to Wainwright a cash commission of 3% of the gross sales price of any Ordinary Shares
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 At the Market Offering Agreement, dated September 26, 2025, between the Company and H.C. Wainwright & Co., LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL documents) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: September 26, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer